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   Cutaneous melanoma is one of the most aggressive and the deadliest form of skin cancers 
characterized by a high degree of intra-tumor heterogeneity harboring mutations in genes involved 
in different signaling pathways. The majority of melanomas are diagnosed in the early stage and are 
treatable with surgical resection with a five-year survival rate ranging 82% to 98% for stages I-II. 
On the other hand, the prognosis of highly aggressive, late stage, melanoma is still very poor. For 
later stage and metastatic melanoma the alkylating agents, Dacarbazine or Temozolomide were the 
earliest treatment option; however, patients easily become resistant to these drugs and they also 
have serious side effects with low overall response and survival rates. 'Targeted therapies', such as 
Vemurafenib and Dabrafenib (BRAF
V600E
 inhibitors) , were developed in order to specifically target mutated 
proteins, with a response rate around 50%; however, most patients relapse within few months [1]. The 
combination of BRAF inhibitors with MEK inhibitors, such as Cobimetinib and Trametinib, achieved 
response rates as high as 70%; however, most patients still face progressive disease even if treated with 
combination therapy, with less than 25% of patients being progression-free at 3 years. Along with the 
development of  'targeted therapies', the immune-checkpoint inhibitors, such as Ipilimumab (a CTLA-4 
inhibitor), Nivolumab and Pembrolizumab (PD-1 inhibitors), were developed to improve the endogenous 
antitumor immune response. However, they are effective in only a subset of patients and may be associated 
with serious side effects and the development of acquired resistance in initially responders [2, 3]. Thus, 
many questions still remain to be answered: what is the best first- and second-line treatment or the 
best treatment sequence? New combinations of drugs, 'targeted therapies' combined with 
immunotherapies, immunotherapies combinations, and sequencing strategies are now underway in 
different clinical trials, highlighting the tendency towards a personalized medical approach [4-9]. 
   Based on these data, we have foreseen this special issue to provide a critical survey of the current 
knowledge of the molecular mechanisms underlying melanoma development; we strongly  believe 
that a deeper understanding of the complex biology network of melanoma will likely lead to the 
identification of novel molecular markers of disease progression/response to therapies and 
biotargets for innovative and complementary therapeutic approaches. 
   Melanoma is a tumor characterized by a high intra-tumor and inter-tumor molecular 
heterogeneity; these levels of tumor heterogeneity are responsible for the lack of accurate diagnosis 
and effective treatments. Therefore, in the last few years, a tremendous effort has been put in the 
development of 'omics' technologies (genomics, transcriptomics, proteomics and metabolomics) 
with the aim to dissect the immense heterogeneity in the biological mechanisms in tumors, 
including melanoma. In their article, Donnelly and coworkers [10] point out how the recently 
available 'omics' platforms allowed the discovery of several novel biomarkers in melanoma; these 
include both tumor tissue-related and circulating biomarkers in liquid biopsies. Tumor tissues 
biomarkers, in addition to the well known BRAF (occurring in 40-60% of patients) and NRAS 
(occurring in 5-15% of patients) genetic alterations, include mutations in genes involved in the 
mechanisms of cell proliferation (KIT, GNA11/GNAQ, NF1, CDKN2A) as well as altered 
epigenetic mechanisms and immune destruction and inflammation mechanisms. On the other hand, 
circulating biomarkers in liquid biopsies of melanoma patients include ctDNA, miRNAs, lncRNAs, 
proteins/metabolites. The pivotal role of these biomarkers in the diagnosis, prognosis and treatment 
response prediction in melanoma is discussed in this article. 
   Angiogenesis, the formation of new blood vessels from pre-existing blood vessels, is a complex 
and highly regulated process that plays a key role in tumor growth and progression. This process 
provides tumor cells with oxygen and nutrients, critical for their continued proliferation and 
aggressiveness. Angiogenesis is regulated by a sequence of well-coordinated events mediated by 
tightly regulated interactions between proangiogenic factors and their receptors expressed on 
vascular cells components (endothelial cells and pericytes) and stromal components forming the 
extracellular matrix. Cho and coworkers [11] discuss the most relevant growth factors and cytokines 
(VEGF-A, bFGF, PIGF, Ang, PDGF, IL-8) endowed with pro-angiogenic activity (endothelial cells 
proliferation and migration, capillary sprouting) and the factors involved in the degradation of the 
extracellular matrix components and in tissue remodelling (uPA, integrins, matrix 
metalloproteinases). The molecular mechanisms of the synergistic activity of these factors in 
promoting melanoma angiogenesis is deeply discussed. Interestingly, high levels of these factors in 
liquid biopsies as well as in tissues biopsies from melanoma patients were reported to be correlated 
with a poor response and reduced overall survival, supporting their role as effective biomarkers of 
tumor development/drug resistance. 
   Tumor cells need high amounts of energy as well as of building blocks for the synthesis of new 
cellular components for their growth and survival. In particular, they display increased activity of 
the glycolysis pathways accompanied by high levels of glucose uptake (the 'Warburg effect') [12]. 
On the other hand, cancer cells can also possess functional mitochondria with active oxidative 
phosphorylation (OXPHOS) and oxygen consumption [13]. Another aspect of the metabolic 
reprogramming in cancer cells is the high rate of fatty acid synthesis and of glutaminolysis, leading 
to the conversion of glutamine into glutamate to fuel the TCA cycle (tricarboxylic acid cycle) and 
into intermediates necessary for aminoacids and nucleotides synthesis [14]. In their article, Ruocco 
et al. [15] discuss the metabolic alterations in melanoma cells, i.e. increased glycolysis and 
mitochondrial glutamine uptake, as well as the intracellular pathways involved in these 
modifications. Mitochondrial dynamics (fission vs. fusion) are also dysregulated in melanoma cells. 
Energetic metabolism of melanoma cells can change in response to extracellular signals, such as 
hypoxia, microenvironment acidification and nutrient deprivation, or intracellular signals modulated 
by the BRAF/MAPK mutated pathways. This altered melanoma metabolism is associated with 
cellular growth, proliferation, invasion and metastasis, and has been shown to  be involved in 
reistance to both BRAF/MEK inhibitors (BRAFi/MEKi) and immunotherapy. Melanoma cells-
microenvironment interaction is bidirectional thus resulting in a biophysical reciprocity whereby 
cancer cells recruit host tissue cells that in turn participates in the progression, metastatic behavior 
and in the metabolic support and regulation of the tumor [16]. In their review, Ruocco et al. [15] 
also address the metabolic interplay between cancer cells and tumor microenvironment that 
modulate immune response and cancer progression. Specifically, tumor glycolysis pathways have a 
strong immunosuppressive role in melanoma; this is related to the increased rates of glycolysis and 
expression of glycolytic enzymes in melanoma cells that generate a glucose-deficient 
microenvironment, in which tumor cells and tumor infiltrating lymphocytes compete for glucose 
uptake, thus interfering with immune surveillance. The authors conclude that a better clarification 
of the metabolic alterations in melanoma cells and the metabolic interplay between cancer cells and 
tumor immune microenvironment may allow the development of new therapeutic strategies 
ameliorating the efficacy of currently used therapies.  
   Epigenetic mechanisms (such as DNA methylation, histone modifications and miRNAs) are 
essential for both a normal development and the maintainence of a tissue-specific gene expression 
pattern. On the other hand, alterations of epigenetic processes can promote altered gene functions 
and malignant cellular transformation [17, 18]. It is actually well accepted that changes in the 
epigenetic landscape represent a hallmark of tumors. Thyagarajan and coworkers [19] address the 
altered expression of miRNAs involved in several key cellular processes of melanoma cells. 
Specifically, miR-21 and miR-155, involved in proliferation and metastatic behavior of cancer cells, 
and miR-211, miR-193, miR-126, miR-145, miR-200 family, involved in apoptosis and tumor 
suppressor signalings, were reported to be up-regulated and down-regulated, respectively, in both 
melanoma tumor tissues (intracellular miRNAs) and serum/plasma samples (extracellular 
miRNAs). The key role of these miRNAs as diagnostic/prognostic biomarkers or molecular targets 
for future therapeutic intervention for malignant melanoma is also deeply discussed. 
   Cancer stem cells (CSCs) are a slow-cycling subpopulation of cells defined by their ability to: 1) 
self-renew indefinitely, 2) form single cell-derived clonal cell populations, and 3) differentiate into 
various cell types [20, 21]. The existence of CSCs in melanoma, as well as their role in tumor 
relapse, is well documented [22]. From the molecular point of view, melanoma CSCs are identified 
and characterized by the expression of stemness markers, such as surface markers; however, the 
role of these markers has been a matter of debate [23]. In melanoma cells, a subpopulation of cells 
expressing the ATP-binding cassette transporter ABCG2, associated with autofluorescence and 
endowed with stemness traits, has been recently identified [24]. In their article, Marzagalli et al. 
[25] discuss the different functional features of melanoma stem cells. In particular, it is reported that 
melanoma CSCs play pivotal roles in the processes of epithelial-to-mesenchymal transition (EMT), 
angiogenesis  and dissemination, mediated by specific intracellular signaling pathways; moreover, 
they are characterized by a unique metabolic reprogramming. Melanoma CSCs are also 
characterized by a low immunogenic profile and by the ability to escape the immune system, 
through the expression of a negative modulation of T cell functions and the secretion of 
immunosuppressive factors. Based on these biological features melanoma CSCs are able to escape 
standard treatments, thus being deeply involved in tumor relapse. Targeting the CSCs 
subpopulation is now considered an attractive treatment strategy; combination treatments, based on 
both CSCs-targeting and standard treatments, will likely increase the therapeutic options for 
melanoma patients. The characterization of CSCs in liquid biopsies from single patients will 
hopefully pave the way towards personalized treatments [25].   
   Melanomas are among the most immunogenic tumors being endowed with a great potential to 
elicit specific adaptive antitumor  immune responses and to respond favorably to immunotherapy. 
Unfortunately, the majority of melanomas rapidly acquire different suppressive mechanisms, which 
generally act in concert, to escape innate and adaptive immune detection and destruction; a 40 to 
65% treatment failure for patients treated with anti-PD-1 and a 70% treatment failure in patients 
treated with anti-CTLA-4 were reported. Intense research into the cellular and molecular events 
associated with melanomagenesis, which ultimately lead to immune suppression, has resulted in the 
discovery of new immune system-therapeutic targets and synergistic combinations of 
immunotherapy, 'targeted therapy' and chemotherapy. In their article, Marzagalli and coworkers 
[26] review the evolution of the immune system during melanomagenesis, the  mechanisms 
exploited by melanoma to suppress anti-tumor immunity and the methods that have been developed 
to restore immunity. After the initial participation of the immune landscape in the control of 
transformation of pre-malignant cells (innate immunity, adaptive immunity), melanoma cells that 
most fit to evade immunity can proliferate leading to tumor progression (analogous to Darwinian 
selection). Specifically, different mechanisms can lead to immune escape: 1) escape of melanoma 
cells from T cell recognition through the modulayion of the expression of highly immunogenic 
proteins (i.e., tumor-associated antigens, TAAs); 2) a dysfunction of T cells which lose their 
effector activities (i.e., cytotoxicity) due to chronic antigen presentation, eventually by non-
professional presenting cells (such as melanoma cells); 3) secretion of cytokines and chemokines by 
melanoma cells leading to the recruitment of pro-tumor, and the suppression or exclusion of anti-
tumor, immune subsets (T cells, macrophages, neutrophils); 4) a rapid reprogramming of melanoma 
cell metabolism, responsible for an inhibitory activity of immune cells activity and proliferation; 5) 
altered expression of miRNAs involved in the modulation of the immune microenvironment in 
malignant melanoma; 6) secretion from tumor cells of exosomes that, through their cargos, can 
exert a pro-apototic activity in immune cells. In summary, this review integrates available 
knowledge on melanoma-specific immunity, molecular signaling pathways and molecular targeting 
strategies that could be utilized for the development of  therapeutics with broader application and 
greater efficacy for melanoma patients, increasing the feasibility of personalized treatment to 
overcome tumor heterogeneity and to achieve greater clinical benefits. 
   Melanoma cells produce a variety of extracellular vesicle (EV) types including shedding vesicles 
and exosomes (EXOs). These EVs are defined by their mechanism of cellular production. To date, 
the majority of EV investigations has focused on melanoma EXOs or small EVs (sEVs). Hood's 
article aims to examine the contribution of natural unmodified melanoma EVs to melanoma 
pathogenesis, and briefly explore their translational potential [27]. In particular, the different roles 
of natural melanoma sEVs in pro-tumor processes, such as angiogenesis, immune regulation and 
modification of tissue microenvironments, are deeply discussed. A thorough examination of these 
processes reveals that they are interdependent, working in concert to support tumor growth and 
survival. Pro-tumor functions attributed to melanoma cells themselves are recapitulated through 
melanoma sEVs, and this ensures a certain degree of redundancy within the melanoma pathogenic 
process, allowing for rapid adaptation of melanoma cells to changing microenvironments, anti-
tumor immune responses, and therapeutic challenges. These specific roles of sEVs in melanoma 
growth and progression are strictly associated with their cargos, such as lipids, proteins, noncoding 
RNA types, particularly miRNAs. Further, as a result of their composition and inherent ability to 
engage the immune system, natural melanoma EVs possess excellent biomarker potential and might 
be used therapeutically as tumor vaccines. 
   Treatment strategies for melanoma patients are known to be associated with development of drug 
resistance and severe side effects. In recent years, natural compounds have been extensively 
investigated for their anti-melanoma effects: tumor growth inhibition, apoptosis induction, 
angiogenesis and metastasis suppression, cancer stem cells eradication. Moreover, a considerable 
number of studies reported the synergistic activity of phytochemicals and standard therapeutics, as 
well as the effectiveness of their synthetic derivatives and novel formulations. The molecular 
mechanisms of the antitumor activity of different natural compounds such as quercetin, fisetin, 
apigenin, luteolin, genistein, epigallocatechin-3-gallate, curcumin, resveratrol, sulforaphane, ursolic 
acid, ginsenosides, tocotrienols and berberine in melanoma cells are highlighted by Fontana and 
coworkers [28]. These authors also underline that, unfortunately, clinical data confirming these 
promising effects in patients and, therefore, the potential application of the most studied natural 
products for melanoma prevention and treatment are still scanty. Given their anticancer activities, 
widely reported in in vitro and preclinical studies, together with their bioavailability and lack of side 
effects, clinical trials addressing the efficacy of these compounds as novel anti-tumor treatment 
strategies are urgently needed. 
   Over the past 20 years, the adjuvant treatment of high-risk melanoma relied on interferon alpha, 
with a consistent effect on relapse-free survival and a less consistent and less impressive effect on 
overall survival, at the cost of severe toxicities, especially when used at high doses. The past 5 years 
have witnessed the results of many practice-changing studies that have dramatically improved the 
landscape of adjuvant therapy in patients with resected, high-risk melanoma, with a reduction of the 
risk of recurrence of about 50% for anti-PD-1 drugs and BRAF+MEK inhibitors compared with 
placebo. In their review, Spagnolo et al. [29] discuss the results of such studies in light of other 
revolutionary changes in the surgical management of high-risk melanoma. In fact, while the 
prognostic value of sentinel lymph node biopsy-based staging was confirmed, completion lymph-
node dissection in patients with positive sentinel node was demonstrated to have no impact on 
overall survival in two randomized trials and is no longer recommended by the most recent clinical 
guidelines. The authors suggest that this conservative approach may lead to reduced risk of surgical 
morbidity and is supported by the outstanding results obtained by adjuvant anti-PD-1 drugs and 
BRAF+MEK inhibitors, limiting the need for lymphadenectomy in patients who relapse in regional 
lymph nodes only despite adjuvant therapy. The authors propose an algorithm for the management 
of resected melanoma at high risk of recurrence in everyday clinical practice, with a look on the 
future directions of the field, giving some insights on neoadjuvant treatments. 
   Despite melanoma has always been described as an immunogenic tumor and a model of cancer 
immunotherapy, “old generation” immunotherapies such as vaccines and cytokines provided an 
impact on survival in a very limited subset of patients. The revolution in the field of melanoma 
immunotherapy was brought by the introduction of 'new generation' immune-checkpoint inhibitors, 
such as anti-CTLA-4 and anti-PD-1 drugs. This strategy proved to be effective not only in 
melanoma, but also in a number of other solid tumors and hematologic malignancies, and was 
considered one of the most important breakthrough in modern oncology. In their article, Queirolo 
and colleagues [30] explain the mechanism of action of such treatments and report the results of the 
main clinical trials that led to their approval. To improve the efficacy of immunotherapy with a 
limited impact on toxicity, the investigation of new combinations and sequences of treatments is 
underway and many clinical trials are ongoing. Despite the high number of treatments and 
combinations of treatments, no validated predictive biomarker exist to select patients, and the 
authors suggest that more efforts should be addressed into the pursuit of predictive biomarkers that 
may guide the clinicians towards personalized medicine.  
   The Guest Editors and the authors of these articles sincerely hope that the recently discovered 
biological features of melanoma addressed in this special issue of the journal Seminars in Cancer 
Biology will be of interest not only for biologists but also for pharmacologists and oncologists 
providing the molecular basis for the identification of novel diagnostic/prognostic markers as well 
as innovative therapeutic strategies, paving the way towards precision medicine. 
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